Clinical Trials Logo

Cannabis Intoxication clinical trials

View clinical trials related to Cannabis Intoxication.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06293040 Not yet recruiting - Clinical trials for Alcohol Intoxication

Vaporized Cannabis Administration and Co-Administration of Alcohol on Impairment

Start date: June 2024
Phase: Phase 1
Study type: Interventional

This human laboratory study will use cognitive, behavioral, and subjective measures to characterize impairment associated with co-use of alcohol and vaporized cannabis. Participants (n=32) will complete 7 double-blind, double-dummy outpatient sessions in randomized order. In each session, participants will self-administer placebo (0 mg THC) or active vaporized cannabis (5 or 25 mg THC, via a handheld vaporizer called the Mighty Medic) and a placebo drink (BAC 0.0%) or alcohol drink calculated to produce a breath alcohol concentration (BAC) of 0.05%. Participants will also complete a positive control session in which the participant administers placebo cannabis and alcohol at a target BAC of 0.08% (the legal threshold for driving impairment in most U.S. states).

NCT ID: NCT04855526 Not yet recruiting - Cannabis Use Clinical Trials

THC + CBD and Memory Study

Start date: April 1, 2022
Phase: Early Phase 1
Study type: Interventional

Memory deficits are one of the most consistently observed cognitive effects of marijuana use. There is evidence that some decrements attributable to the primary psychoactive ingredient, delta-9-tetrahydrocannabinol (THC), may be attenuated by cannabidiol (CBD). This study will help us learn more about the relationship between THC and CBD consumption with memory processes. A combination of MRI and neuropsychological tests (which are computer and paper/pencil tasks) will be used to measure the neurocognitive and behavioral impacts of THC and CBD use.